Drug Profile

BH 1657

Alternative Names: anti-TNFα/IL-17A Bispecific antibody - Hanmi Pharmaceutical; anti-TNFα/IL-17A BsAb - Hanmi Pharmaceutical; BH1657

Latest Information Update: 28 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hanmi Pharmaceutical
Class Antirheumatics; Bispecific antibodies
Mechanism of Action Interleukin 17 inhibitors; Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Feb 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea (Parenteral)
16 Jan 2019 Hanmi Pharmaceutical announces intention to submit IND to US-FDA and C-FDA for Rheumatoid Arthritis in the fourth quarter of 2019
10 Jan 2019 Preclinical trials in Rheumatoid arthritis in South Korea (Parenteral) before January 2019 (Hanmi Pharmaceutical pipeline, January 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com